PT - JOURNAL ARTICLE AU - Buchert, Rebecca AU - Schenk, Elisabeth AU - Hentrich, Thomas AU - Weber, Nico AU - Rall, Katharina AU - Sturm, Marc AU - Kohlbacher, Oliver AU - Koch, André AU - Rieß, Olaf AU - Brucker, Sara Y. AU - Schulze-Hentrich, Julia M. TI - Genome sequencing and transcriptome profiling in twins discordant for Mayer-Rokitansky-Küster-Hauser syndrome AID - 10.1101/2022.06.01.22275812 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.01.22275812 4099 - http://medrxiv.org/content/early/2022/06/06/2022.06.01.22275812.short 4100 - http://medrxiv.org/content/early/2022/06/06/2022.06.01.22275812.full AB - Objective Mayer-Rokitansky-Küster-Hauser syndrome (MRKH) is a rare congenital disease manifesting with aplasia or severe hypoplasia of uterine structures. Even though extensive studies have been performed, for the majority of cases the etiology remains unclear. In this study, we sought to identify genetic causes in discordant monozygotic (MZ) twins using genome sequencing of blood of both twins as well as uterine tissue of the affected twin. In addition, we profiled the endometrial transcriptome of affected twins to compare perturbations with those of sporadic MRKH cases.Results First, analyzing the data under the assumption that a variant solely identified in the affected twin or affected tissue could cause the phenotype, we identified a mosaic variant in ACTR3B with a high allele frequency in affected tissue, a low allele frequency in blood of the affected twin and almost absent in the blood of the unaffected twin. Since ACTR3B has not been reported for genitourinary anomalies before, clinical relevance of the variant needs to be clarified.Second, examining the data for candidate genes previously implied in MRKH, we detected a pathogenic variant in GREB1L in one twin pair and their unaffected mother showing a reduced phenotypic penetrance. Furthermore, two variants of unknown clinical significance in PAX8 and WNT9B were identified. Analysis for copy number and structural variants revealed no discordant variants in the twins or variants in candidate genes or regions.Third, we conducted transcriptome analysis of affected tissue and observed widespread perturbations largely similar to those in sporadic MRKH cases. These shared transcriptional changes were enriched for terms associated with estrogen and its receptors pointing at a key role of estrogen in MRKH pathology.Conclusion Our study on genome sequencing of blood and uterine tissue of discordant twins is the most extensive study performed on twins discordant for MRKH so far. Nevertheless, no clear pathogenic differences in the twins or between blood and tissue samples were detected. This points towards a more complex etiology of MRKH less dependent on genetic differences and more determined by epigenetic changes or environmental factors. Our transcriptome data showed a clear overlap with gene expression data of sporadic MRKH cases, indicating that the etiology for MRKH in discordant twins and sporadic cases is largely similar.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a project grant of the Deutsche Forschungsgemeinschaft (DFG 351381475; BR 5143/5-1, AOBJ: 639534; KO 2313/7-1, AOBJ: 639535; RI 682/15-1, AOBJ: 639536) and through funding of the NGS Competence Center Tuebingen (NCCT-DFG, project 407494995). This study is associated with the TwinHealth initiative. JMS-H was supported by the solveRD consortium (European Unions Horizon 2020 research and innovation programme under Grant Agreement No. 779257).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the University of Tuebingen (approval number: 205/2014BO1) and informed consent for genetic studies was obtained from each patient before recruitment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome and RNA-sequencing data that support the findings of this study have been deposited in the European Genome-phenome Archive (EGA) (primary accession number pending).